Recently, Vaibhav Vidwani, an equity research analyst at Bonanza Portfolio, had suggested to to enter Aurobindo Pharma. The stock shows strong potential and the ability to perform well in the long run, he stated.
The company’s fourth-quarter profit stayed almost flat in the fourth quarter of financial year 2024-25, thereby missing analysts’ estimates.
The Hyderabad-based bulk and generic drugmaker posted a profit of Rs 903.5 crore in the quarter ended March 31, 2025, according to a disclosure to the stock exchanges. That compares with the Rs 1,013-crore consensus estimate of analysts tracked by Bloomberg.
Shares of the pharmaceutical brand closed 0.25% higher at Rs 1,104.20 apiece, nearly at par with a 0.29% advance in the benchmark NSE Nifty 50.
